54 results about "In vitro binding" patented technology

Embodiments of the present invention utilize a more efficient CDR grafting technique to generate humanized versions of the T84.66 antibody. The technique used to generate these antibodies utilizes crystallographic structural data to select an immunoglobulin framework having maximum structural overlap with a non-human donor molecule. This technique was used to develop humanized T84.66 antibodies exhibiting in vitro binding affinity and specificity for carcinoembryonic antigen (CEA) nearly identical to that of T84.66 and the ability to specifically target tumors expressing CEA in vivo.

The invention relates to a soybean ethylene responsive factor (ERF) transcription factor, and a coding gene and salt tolerance application thereof, and belongs to the field of genetic engineering. The amino acid sequence of the soybean ERF transcription factor is Sequence No.2, the amino acid sequence of the coding gene of the soybean ERF transcription factor is Sequence No.1, and the invention provides application of the soybean ERF transcription factor to salt tolerance of a transgenic plant. A GmERF7 transcription factor gene related with the soybean salt tolerance is cloned, and the expression mode of the gene in soybean, the in-vitro combination of the gene with an adversity element, and transcriptional regulation activity of the gene are researched, the salt tolerance of wild type tobacco and tobacco with trans GmERF7 gene is compared, basis is provided for the effective application of the soybean ERF transcription factor, and the invention has significance for improvement on stress resistance of plants, particularly cultivation of soybean varieties with high salt tolerance.

An isolated antiviral peptide is characterized by the amino acid sequence GDEPLENYLDTEYF and a significant in vitro binding affinity for HIV-1 gp 120 and gp 41, and human CD4 cells. The peptide exhibits anti-retroviral activity in vivo, particularly anti-HIV-1 activity.

Embodiments of the present invention utilize a more efficient CDR grafting technique to generate humanized versions of the T84.66 antibody. The technique used to generate these antibodies utilizes crystallographic structural data to select an immunoglobulin framework having maximum structural overlap with a non-human donor molecule. This technique was used to develop humanized T84.66 antibodies exhibiting in vitro binding affinity and specificity for carcinoembryonic antigen (CEA) nearly identical to that of T84.66 and the ability to specifically target tumors expressing CEA in vivo.

The invention belongs to the technical field of plant extraction and particularly relates to alpinia oxyphylla leaf extract and a preparation method and application thereof. The preparation method of the alpinia oxyphylla leaf extract includes: taking alpinia oxyphylla leaves, adding ethanol, heating for extraction, and concentrating and drying extracted liquid to obtain ethanol total extract; dispersing the ethanol total extract into water, sequentially using petroleum ether, ethyl acetate and n-butanol for extraction, and volatizing solvent of each extract to respectively obtain petroleum ether part extract, ethyl acetate part extract and n-butanol part extract. In vitro and in vivo experiments show that the alpinia oxyphylla leaf extract has certain hypoglycemic effect in vitro and in vivo.

The present invention relates to an [18F]fluoromethyl group-introduced radiotracer for positron emission tomography for targeting brain neuroinflammation, a synthesis thereof, and a method for evaluating biological results using the same. In the present invention, a fluoromethyl group-introduced fluorine-18 labeled radiotracer was prepared by introducing [18F]fluoroiodomethane, in which a prosthetic group diiodomethane is labeled with fluorine-18, into PBR28-OH through two stages, or substituting fluorine-18 using a triazolium triflate precursor in one stage at high yield. It was confirmed that, as a result of comparison and evaluation with exiting known [11C]PBR28 in view of in vitro binding affinity, fat affinity, and pharmacodynamic characteristics in a brain neuroinflammation model, the fluoromethyl group-introduced fluorine-18 labeled radiotracer had similar binding affinity and fat affinity to [11C]PBR28. Further, it was confirmed from the PET image comparison and evaluation in the brain neuroinflammation model that the fluoromethyl group-introduced fluorine-18 labeled radiotracer exhibited excellent selective / specific absorption in the inflammatory region more quickly and had high stability at the brain neuroinflammation site. According to the present invention, with respect to the synthesis of the novel fluoromethyl group-introduced fluorine-18 labeled radiotracer for PET targeting brain neuroinflammation and the diagnosis of brain neuroinflammation diseases, fluorine-18 having a relatively longer half-life than [11C]PBR28 was capable of being excellently labeled through the minimum structural change, and its excellent selective and specific imaging and pharmacodynamic advantages were verified, and thus a useful radiotracer for PET targeting brain neuroinflammation can be expected.

The invention relates to the technical field of meat product processing, in particular to a method for preparing pickled meat with pickled vegetables using Suhuai pig pork belly as a raw material. The processing method of the present invention uses Suhuai pig pork belly and Shaoxing preserved vegetables as raw materials. The pork belly is cut, colored and sliced, and the preserved vegetables are washed and fried, followed by steps such as sauce adjustment, steaming, packaging, pre-cooling, and quick-freezing. Pork with preserved vegetables. The in vitro digestion model is used to simulate the digestion of food in the gastrointestinal tract in vivo, and the bioavailability of food is reflected by the degree of food digestion. Flavor is an important indicator of food sensory quality, which directly affects consumers' choices. The selection of raw materials is the basis of meat processing. The invention combines in vitro digestion, headspace solid-phase microextraction-gas chromatography and sensory evaluation to optimize the process of raw material varieties. The purpose of the present invention is to produce standardized pickled meat with pickled vegetables with excellent sensory quality and nutritional quality, so as to meet consumers' requirements for food safety, health, convenience and speed.

Embodiments of the present invention utilize a more efficient CDR grafting technique to generate humanized versions of the T84.66 antibody. The technique used to generate these antibodies utilizes crystallographic structural data to select an immunoglobulin framework having maximum structural overlap with a non-human donor molecule. This technique was used to develop humanized T84.66 antibodies exhibiting in vitro binding affinity and specificity for carcinoembryonic antigen (CEA) nearly identical to that of T84.66 and the ability to specifically target tumors expressing CEA in vivo.

A synthesized or isolated influenza virus replication-inhibiting peptide that competitively inhibits protein-protein interaction of the PA and PB1 of both influenza Virus Types A and B and novel in vitro binding screen to identify peptides with antiviral activity against influenza viruses of both type A and B is disclosed. In addition to the well-known pandemic influenza A viruses (such as the 1918 ''Spanish'' flu or H5N1), both type A and B viruses contribute greatly to the annual recurring epidemics that cause the vast majority of human cases and medical cost. Surprisingly, it was found that the novel virus replication-inhibiting, are able to inhibit protein-protein interaction of the PA and PB1 subunits of the heterotrimeric viral RNA polymerase complex of both influenza virus types A and B. The viral polymerase sub- unit interaction domain turned out as an effective target for the new antivirals, as correct assembly of the three viral polymerase subunits PB1, PB2 and PA is required for viral RNA synthesis and infectivity.

The invention relates to an application of dendrobium officinale polysaccharide in preparation of a drug for treating tumors by targeting tumor-associated macrophages, and belongs to the technical field of botanical drugs. Through the combination of in-vitro and in-vivo experiments, it is found for the first time that the dendrobium officinale polysaccharide can recognize TLR2 receptors on the surfaces of tumor-associated macrophage membranes in a targeted manner, the TAMs are induced to be polarized from M2 type to M1 type through mediation of the TLR2 receptors, then the tumor killing activity of CD8+T cells is promoted, immune escape generated by Tregs is inhibited, and therefore an anti-tumor effect is achieved synergistically. The application of the dendrobium officinale polysaccharide as the anti-tumor drug is developed, and a new possibility is provided for treating tumors by targeting the TAMs.

A series of N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinealkylamides was prepared and their affinity for serotonin 5-HT7, 5-HT1A, and 5-HT2A receptors was measured using in vitro binding assays. In relation to 5-HT7 receptor affinity, receptor binding studies indicated that: (i) the optimal alkyl chain length was five methylenes; (ii) an unsubstituted 1,2,3,4-tetrahydronaphthalenyl nucleus was selected for further substitutions; and (iii) the substitution pattern of the aryl ring linked to the piperazine ring played a significant role. Several compound with high affinity for 5-HT7 receptors were identified. Among them, 4-(2-methoxyphenyl)-N-(1,2,3,4-tetrahydronaphthalen-1-yl)-1-piperazinehexanamide (28), 4-(2-acetylphenyl)-N-(1,2,3,4-tetrahydronaphthalen-1-yl)-1-piperazinehexanamide (34), 4-(2-methylthiophenyl)-N-(1,2,3,4-tetrahydronaphthalen-1-yl)-1-piperazinehexanamide (44), 4-(2-hydroxyphenyl)-N-(1,2,3,4-tetrahydronaphthalen-1-yl)-1-piperazinehexanamide (46), 4-(2-methylphenyl)-N-(1,2,3,4-tetrahydronaphthalen-1-yl)-1-piperazinehexanamide (49) were assayed for the 5-HT7 receptor mediated relaxation of substance P-induced guinea-pig ileum contraction. Compounds 28, 44, and 49 behaved as full agonists, compound 34 as a partial agonist, whereas derivative 46 acted as an antagonist.

The present invention provides novel human fins related tyrosine kinase 3 (FLT3) antigen binding proteins, such as antibodies, having improved FLT3 binding affinity, and / or anti-tumor activity. The FLT3 antibodies of the invention were generated by mutation of a parent FLT3 antibody and tested in in vitro in binding assays as well as in vivo in a mouse tumor model and in human patient tumor samples. The antibodies of the invention are provided as monospecific constructs or in a bispecific FLT3×CD3 antibody format and show excellent target affinity and / or tumor cell killing. The present invention also relates methods for producing the antigen binding proteins of the invention as well as nucleic acids encoding them, vectors for and host cells for their expression. The invention further relates to methods of treating or diagnosing a disease such as leukemia using an FLT3 antigen binding protein (ABP) of the invention.

The invention belongs to the technical field of gene engineering and particularly relates to a DypB active protein heterology high expression method and application. Aiming at the problem that existing DypB protein has no activity in hyterology expression and only can generate activity by being combined with heme in vitro, the invention provides the DypB active protein heterology high expression method and application. The method disclosed by the invention comprises the steps of integrating related genes expressing the heme into host cells through genetic recombination to enable a host to have high-concentration heme, then constructing DypB into a recombinant vector and leading the recombinant vector into an expression host with high heme expression; thus, heterology high expression of the DypB active protein can be achieved. According to the method disclosed by the invention, the heme is integrated in the expression host to be synthesized into the related genes to improve the in-vivo accumulation concentration of the heme, then the DypB is expressed a lot through a cold induction mode, and the DypB has activity for degrading lignin after being expressed by the host.

The invention discloses a construction method for distinguishing a model of the activity effect of PBDEs derivatives on enoyl-ACP reductase. The construction method comprises the steps of receptor andligand modeling, molecular docking and molecular dynamics simulation. The calculation result of the model is consistent with the result of an in-vitro binding activity determination experiment, and the result shows that the construction method of the model can accurately calculate the activity effect of the PBDEs derivatives on the enoyl-ACP reductase.

The invention discloses an O-type foot-and-mouth disease CTL epitope peptide, a screening method and application thereof. The CTL epitope peptide is composed of nine amino acid residues, and its amino acid sequence is: Ala-Thr-Arg-Val-Thr-Glu-? Leu-Leu-Tyr. The epitope peptide can have strong binding ability with SLA-I proteins derived from different strains of pigs and can cause cytotoxic immune response, and is suitable for the preparation of vaccines for the prevention and treatment of various strains of porcine foot-and-mouth disease viruses, and has a wide range of applications. The invention uses the constructed six-strain pig SLA-I single-chain molecule to bind the CTL mimetic epitope peptide of foot-and-mouth disease virus in vitro, mass spectrometry to screen the polypeptide that can bind to the complex, and through ELISPOT detection, it is determined that it can induce T cell immune response Capable mimotope peptides. The invention provides a method for screening and identifying a large number of CTL epitopes of foot-and-mouth disease virus in the future, and lays a foundation for developing a porcine foot-and-mouth disease multi-epitope vaccine.

The invention relates to the field of biological medicine, in particular to calprotectin participating in in-vitro binding of NY-ESO-1 and DC cells in bone marrow. The inventor of the invention explores that the NY-ESO-1 protein can form a polymer structure even in loading buffer with beta-mercaptoethanol with the conventional concentration; the polymerization reaction of the NY-ESO-1 is mediated by intermolecular disulfide bond; binding of the NY-ESO-1 and immature dendritic cells of human and mice in vitro is associated with the polymerization structure of the NY-ESO-1; TLR4 influences the in-vitro binding of the NY-ESO-1 and the DC cells in the bone marrow; the binding of the NY-ESO-1 and the immature dendritic cells of human and the mice in vitro can be realized through the effect of the calprotectin; polymer oligomerization reduces the binding quantity of the TLR4 and the NY-ESO-1; the polymer structure of the NY-ESO-1 and the TLR4 in a host participate in the immuno-sphere antibody reaction; and improvement of Artv1(wtArt) and CA9 gene immunogenicity depends on the NY-ESO-1 gene fusion expression. The invention proves that the calprotectin participates in in-vitro binding of the NY-ESO-1 and the DC cells in the bone marrow.

The invention discloses a myrtle polysaccharide P3, its separation and purification method and its use in the preparation of blood lipid-lowering drugs. The polysaccharide contains the following molar percentages of monosaccharides: 9.97% of ribose, 2.40% of rhamnose, and 64.51% of arabinose , xylose 6.14%, mannose 5.39%, glucose 1.74%, galactose 9.85%. The experimental results of the present invention show that myrtle polysaccharide P3 has a certain ability to bind bile salts in vitro. With cholestyramine as a positive control, the binding rate of cholestyramine to each bile salt is calculated as 100%. The relative binding rates of myrtle polysaccharide P3 to sodium taurocholate, sodium glycocholate, and sodium cholate were 29.65%, 45.84%, and 51.90%, respectively.

The invention relates to the field of medicine, in particular to a polypeptide capable of inhibiting the expression of somatostatin and treating liver cancer. Its sequence is GGLGLPFLATQNAAS, which is a brand-new sequence, which promotes the binding of somatostatin in vitro, and improves the survival rate of tumor-bearing mice in vivo, and has potential new drug development value.

The invention provides an arsenic binding protein A10, a recombinant vector containing a coding gene of the protein and an engineering strain containing the recombinant vector. The arsenic binding protein A10 disclosed by the invention can be used for improving the resistance of a strain to arsenite and methyl arsenite, improving the accumulation efficiency of the strain to the arsenite and the methyl arsenite and combining the arsenite and the methyl arsenite in vitro. The engineering bacterium has strong resistance to arsenite and methyl arsenite, the binding efficiency of the target protein A10 to arsenite and reducing monomethyl arsenic is as high as 92.24% and 76.69%, the binding efficiency of the target protein A10 to arsenite and reducing monomethyl is as high as 96.70% and 83.33%, and arsenic in a culture environment can be effectively removed. The protein A10 with strong binding capacity to arsenite and methyl arsenite provides a novel bioremediation material for arsenic pollution remediation in paddy fields and water environments.